You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK):前三季淨利44.84億元 同比增長24.49%
格隆匯 10-29 17:05

格隆匯10月29日丨上海醫藥(02607.HK)公佈三季報,2021年1-9月(下同),公司主營業務繼續保持較快增長,實現營業收入1,609.73億元(幣種為人民幣,下同),同比增長14.72%,其中醫藥工業實現銷售收入187.87億元,同比增長8.16%;醫藥商業實現銷售收入1,421.86億元,同比增長15.64%。

報吿期內,公司實現歸屬於上市公司股東的淨利潤44.84億元,同比增長24.49%。醫藥工業和商業主營業務利潤繼續保持良好增長態勢,其中工業板塊貢獻利潤16.79億元,同比增長1.90%,商業板塊貢獻利潤20.82億元,同比增長19.04%,參股企業貢獻利潤7.69億元,同比下降1.94%。歸屬於上市公司股東的扣除非經常性損益的淨利潤為35.45億元,同比增長8.14%,非經常性損益主要來自上藥雲健康B輪融資後出表形成的一次性收益。公司研發費用投入13.67億元,同比增長31.38%,還原研發費用後歸屬於上市公司股東的淨利潤同比增長26.04%。公司繼續保持穩健的營運質量,實現經營性現金淨流入29.25億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account